Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
NCT ID NCT04853017
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack cancer cells carrying specific KRAS mutations. The main goal was to check safety, and researchers also looked for reductions in tumor DNA in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ELI-002 (a combination of an immune-stimulating compound and cancer-targeting peptides)
- What this could lead to
- If successful, this could lead to a new immunotherapy option for people with certain KRAS-mutated cancers, potentially helping to keep the disease from coming back after standard treatment.
- What could go wrong
- This is a very early Phase 1 trial with only 25 participants, so it is too soon to know if the treatment works. The main goal was safety, not effectiveness, and many early-stage therapies do not move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
Tennessee Oncology - Centennial Clinic
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a plasma beam stop colon polyps from coming back?
- Can a new drug shield nerves from Chemotherapy's side effects?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?